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Abstract
Objectives: Clinical responses achieved with FLT3 kinase inhibitors in acute myeloid leukemia (AML) are typically transient
and partial. Thus, there is a need for identification of molecular mechanisms of clinical resistance to these drugs. In response,
we characterized MOLM13 AML cell lines made resistant to two structurally-independent FLT3 inhibitors.
Methods: MOLM13 cells were made drug resistant via prolonged exposure to midostaurin and HG-7-85-01, respectively. Cell
proliferation was determined by Trypan blue exclusion. Protein expression was assessed by immunoblotting,
immunoprecipitation, and flow cytometry. Cycloheximide was used to determine protein half-life. RT-PCR was performed
to determine FLT3 mRNA levels, and FISH analysis was performed to determine FLT3 gene expression.
Results and Conclusions: We found that MOLM13 cells readily developed cross-resistance when exposed to either
midostaurin or HG-7-85-01. Resistance in both lines was associated with dramatically elevated levels of cell surface FLT3 and
elevated levels of phosphor-MAPK, but not phospho-STAT5. The increase in FLT3-ITD expression was at least in part due to
reduced turnover of the receptor, with prolonged half-life. Importantly, the drug-resistant phenotype could be rapidly
reversed upon withdrawal of either inhibitor. Consistent with this phenotype, no significant evidence of FLT3 gene
amplification, kinase domain mutations, or elevated levels of mRNA was observed, suggesting that protein turnover may be
part of an auto-regulatory pathway initiated by FLT3 kinase activity. Interestingly, FLT3 inhibitor resistance also correlated
with resistance to cytosine arabinoside. Over-expression of FLT3 protein in response to kinase inhibitors may be part of a
novel mechanism that could contribute to clinical resistance.
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Introduction
A constitutively activated, mutated version of the class III receptor
tyrosine kinase, FLT3 (Fms-Like Tyrosine kinase-3; STK-1, human
Stem Cell Tyrosine Kinase-1; or FLK-2, Fetal Liver Kinase-2), is
expressed in approximately 30% of AML patients and a subset of
ALL patients [1]. The most prevalent form of mutant FLT3, present
in approximately 20–25% of AML patients and less than 5% of
myelodysplastic syndrome (MDS) patients, occurs as internal tandem
duplications (ITD) within the juxtamembrane domain [2–6]. Gain-of-
function point mutants in FLT3, typically in the kinase activation loop
(often at position 835) [7] are detected in about 7% of patients with
AML. Additional FLT3 mutations that have been identified include
N841I [8], Y842C [9], and novel, weakly activating point mutations
in a 16 amino acid stretch of the FLT3 juxtamembrane [10].
Thus, mutant FLT3 represents an attractive target for the
therapy of AML. Several FLT3 inhibitors, including the N-
indolocarbazole, PKC412 (midostaurin; N-benzoyl-staurosporine,
Novartis Pharma AG) [11], have shown sufficient efficacy and
safety profiles to warrant further study in combination with
standard therapies in advanced clinical trials. However, inhibitors
of FLT3 have generally elicited partial and transient clinical
responses in early trials [12,13]. The observed suboptimal clinical
responses, coupled with detection of drug-resistant leukemic blast
cells in FLT3 inhibitor-treated AML patients, have made
understanding clinical resistance to FLT3 inhibitors a priority.
The cause for clinical resistance has not yet been identified and
there is little evidence for FLT3 mutations that are analogous to
the BCR-ABL gate-keeper mutations in CML, observed in
response to imatinib and related compounds.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25351In a phase II trial of the FLT3 inhibitor, lestaurtinib (CEP701),
which tested the agent in older AML patients (both mutant FLT3-
and wild-type FLT3-expressing) that were not considered fit for
intensive chemotherapy, the majority of clinical responses
observed were only of short duration (25 days was the median
time to disease progression) [14]. Interestingly, in this study, most
(13/14) of patients in which blast surface FLT3 expression was
able to be measured showed an elevation in blast surface FLT3
expression while treatment with lestaurtinib ensued. Authors of
this study speculated that this up-regulation of FLT3 receptor
expression might have contributed to the limited clinical benefit of
dose escalation from 60 mg to 80 mg, and thus might represent a
potential mechanism of drug resistance.
Several recent cell line-based studies have attempted to
investigate possible underlying mechanism(s) of FLT3 inhibitor
resistance, using mutant FLT3-expressing cell lines exposed for
prolonged periods of time to increasing concentrations of various
inhibitors [15–17]. Culture of the MV4-11 cell line (which has
FLT3-ITD in both alleles) over a span of several months in the
presence of increasing concentrations of the FLT3 inhibitor, ABT-
869, led to an ABT-869-resistant line characterized by activation
of STAT pathways and over-expression of the IAP, survivin
[16,18,19]. Similar long-term exposure of MV4-11 cells to
PKC412 led to a PKC412-resistant line characterized by clonal
alterations at Chromosome 13q, and DNA-oligonucleotide
microarray analysis and RT-PCR revealed modest changes in
levels of Mcl-1 and FLT3 ligand, although a sizable up-regulation
of the Notch signaling ligand, JAG1 [17]. Ras mutations were
found in another assay system that utilized MOLM14 cells (an
AML-M5 line having one wt FLT3 allele and one FLT3-ITD
allele) made resistant to FLT3 inhibitors, CEP-5214 [20] and
CEP-701 [21] following long-term exposure to these agents [15].
Thus, there are a number of potentially significant contributors
to FLT3 inhibitor resistance, generally characterized by persistent
activation of signaling through unknown mechanisms, activation
of survival pathways, or potentially activation of bypass pathways,
such as Ras. It is not yet clear whether these various mechanisms
of resistance are specific to each inhibitor or each cell line.
Here we have used two structurally distinct FLT3 kinase
inhibitors, PKC412 [11], and the novel type II ATP competitive
inhibitor, HG-7-85-01 [22], to generate resistant cell lines using
the human AML cell line, MOLM-13. The cell lines obtained
were cross-resistant, and in both cases, resistance was associated
with a striking over-expression of the mutant FLT3 receptor, a
finding reflective of the previously observed up-regulation of
surface FLT3 receptor expression in FLT3 inhibitor-treated
patients [14]. The mechanism and effects of this type of tyrosine
kinase inhibitor resistance are described in this study.
Materials and Methods
Cell lines and cell culture
The human AML-derived, FLT3-ITD-expressing cell line,
MOLM-13 (DSMZ (German Resource Centre for Biological
Material), was engineered to express luciferase fused to neomycin
phosphotransferase (pMMP-LucNeo) by transduction with a VSVG-
pseudotypedretrovirusaspreviously described [23]. For development
of PKC412-resistant MOLM13-luc+ cells (MOLM13-R-PKC412),
MOLM13-luc+ cells were started in culture in the presence of 1 nM
PKC412 for approximately 3 weeks. From day 22 through day 79
post-commencement of culture in the presence of inhibitor, the
concentration of PKC412 was gradually increased from 1 nM to
10 nM. From day 79 through day 96, the concentration of PKC412
was gradually increased from 10 nM to 50 nM.
For development of HG-7-85-01-resistant MOLM13-luc+ cells
(MOLM13-R-HG-7-85-01), MOLM13-luc+ cells were started in
culture in the presence of 1 nM HG-7-85-01 for approximately 3
weeks. From day 22 through day 79 post-commencement of
culture in the presence of inhibitor, the concentration of HG-7-85-
01 was gradually increased from 1 nM to 5 nM. From day 79
through day 96, the concentration of HG-7-85-01 was either
maintained at 5 nM or was gradually increased to 10 nM.
Development of PKC412-resistant cells derived from drug-
resistant colonies (MOLM13-R-PKC412 (CFU)) is described in
the supplementary data section.
Cell lines were cultured with 5% CO2 at 37uC in RPMI
(Mediatech, Inc., Herndon, VA) with 10% fetal calf serum (FCS)
and supplemented with 1% L-glutamine. Culture media for
PKC412-resistant MOLM13-luc+ cells derived from either long-
term culture or drug-resistant colonies was supplemented with a
final concentration of 50 nM PKC412. Culture media for HG-7-
85-01-resistant MOLM13-luc+ cells was supplemented with a final
concentration of 5 nM or 10 nM HG-7-85-01, as indicated for
each study.
Chemical compounds and biologic reagents
HG-7-85-01 was synthesized in the laboratory of Dr. Nathanael
Gray, DFCI, Boston, MA. PKC412 was synthesized by Novartis
Pharma AG, Basel, Switzerland. Compounds were initially
dissolved in DMSO to make 10 mM stock solutions, and then
were serially diluted to obtain final concentrations for in vitro
experiments. Cycloheximide (Sigma, St Louis, MO) was prepared
as a stock solution (10 mg/mL).
Antibodies and immunoblotting
All antibodies used for immunoblotting were diluted at 1:1000.
Anti-p-Tyr (clone 4G10) was purchased from Upstate Biotechnol-
ogy (Lake Placid, NY). Purchased from Santa Cruz Biotechnology
(Santa Cruz, CA) were anti-FLT3/Flk-2 (C-20) (rabbit, sc-479),
phospho-STAT3 (rabbit, #9131), total STAT3 (C-20) (rabbit, Sc-
482). Bcl-2 (Cat # 1017-1, rabbit mAb) was purchased from
EPITOMICS (Burlingame, CA). DR-5 (ab47179, rabbit) was
purchased from AbCam. Antibodies purchased from Cell
Signaling Technology (Danvers, MA) included phospho-MAPK-
p44/42 (T202/Y204) (rabbit, #9101S), total MAPK (rabbit,
#9102), p-MEK1/2 (S217/221) (41G9) (rabbit, #9154S), total
MEK1/2 mAb (47E6) (rabbit, #9126), phospho-STAT5 Tyr694
(rabbit, #9351S), total STAT5 (3H7) (rabbit, #9358 mAb), P27
Kip1 (rabbit, #2552), Mcl-1 (D35A5) (rabbit mAb #5453), Bax
(D2E11) mAb (#5023), BAK (rabbit, #3814S), BIM (rabbit,
#2819), and BID (7A3) (mouse Ab).
Loading controls included alpha-tubulin (Sigma, St Louis, MO)
(1:5000 dilution), beta-actin (mouse monoclonal, Sigma, St Louis,
MO) (1:1000 dilution), and GAPDH (Cell Signaling Technology,
Danvers, MA) (1:1000 dilution).
Protein lysate preparation and immunoblotting were carried out
as previously described [11].
Proliferation studies
Cell counts for proliferation studies were obtained using the
trypan blue exclusion assay, as previously described [11]. Error
bars represent the standard error of the mean for each data point.
Flow cytometry
Drug-sensitive and drug-resistant MOLM13-luc+ cells were
stained in the dark for 20–30 minutes with a CD135-PE antibody
for detection of FLT3 receptor or an IgG aPE(1) antibody was used
FLT3 Inhibitor Resistance
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suggestions). Following the staining, FACS analysis was performed.
RT-PCR
RNA was isolated from cells using an RNeasy kit from Qiagen
(Valencia CA). cDNA was generated using the TaqMan Reverse
Transcription Kit from Applied Biosystems (Foster City, CA).
Quantitative polymerase chain reaction was performed in
triplicate on a 7500 real-time PCR system (Applied biosystems)
using SYBR Green Master Mix from Applied Biosystems using the
following primers: forward, CAGATGCAGAAGAAGCGATG
and reverse, TGAGCCTGCGGAGAGAGTAG. Data are ex-
pressed as mean fold change of three replicates. For the internal
control: HPRT, forward, GAACGTCTTGCTCGAGATGTG
and reverse, CCAGCAGGTCAGCAAAGAATT.
FISH analysis
FISH analysis was performed to assess the copy number of FLT3
in three human cancer cell lines: MOLM13 (MOLM13-S),
PKCRes+ (MOLM13-R-PKC412), and PKCRes- (MOLM13-R-
PKC412, drug-deprived for .3 weeks). Briefly, the cells were
harvested and treated with 0.075 M KCl for 20 min at room
temperature, and subsequently fixed with 3:1 Methanol: Acetic Acid.
The fixed cells were hybridized in a humidified chamber with a
human chromosome 13 specific reference probe (RP11-151A6, green
color) and a human FLT3 probe (RP11-136G6, orange color) at
37uC for 48 hr. The slides were washed with 50% Formamide/
2XSSC (pH 7.2), 2X SSC, and 1XPBD. The slides were stained with
DAPI and examined with Olympus BX51 microscope for signals.
Results
FLT3 inhibitor-sensitive (MOLM13-S) cells and FLT3
inhibitor-resistant (MOLM13-R) cells: Comparison of
proliferation in the presence of inhibitor, cellular tyrosine
phosphorylation, and FLT3 autophosphorylation
MOLM13-luc+ cells were grown in the presence of gradually
increasing concentrations of PKC412 and HG-7-85-01, respec-
tively, over a span of approximately three months. Cells made
resistant to PKC412 (MOLM13-R-PKC412) (average IC50
derived from several experiments of approximately 55 nM) were
several fold less sensitive to PKC412 than drug-sensitive cells
(MOLM13-S) (average IC50 derived from several experiments of
approximately 11 nM) (Figure 1A). Similarly, the sensitivity of cells
made resistant to HG-7-85-01 (MOLM13-R-PKC412) (average
IC50 derived from several experiments of approximately 8 nM)
was several fold lower than that of MOLM13-S cells (average
IC50 derived from several experiments of approximately 2 nM)
(Figure 1B). In addition, MOLM13-R-PKC412 cells showed less
sensitivity to HG-7-85-01 than MOLM13-S cells (Figure 1C), and
MOLM13-R-HG-7-85-01 cells showed sensitivity to PKC412 that
was comparable to that shown by MOLM13-R-PKC412
(Figure 1D). These results suggest cross-resistance of MOLM13-
R-HG-7-85-01 and MOLM13-R-PKC412, which may be due to
their shared over-expression of mutant FLT3.
Levels of phospho-FLT3, total cellular tyrosine phosphoryla-
tion, and total FLT3 are higher in MOLM13-R-PKC412 and
MOLM13-R-HG-7-85-01 cells than in MOLM13-S cells
(Figure 1E–F). A parallel study of PKC412-resistant cells derived
from pooled colonies growing in methylcellulose in the presence of
100 nM PKC412 (MOLM13-R-PKC412-CFU) similarly showed
elevated phospho-FLT3 and total FLT3 protein levels, as
compared to MOLM13-S cells (Figure S1).
MOLM13-S cells and MOLM13-R cells: Comparison of
FLT3 kinase activity and tyrosine phosphorylation of
signaling molecules associated with FLT3 signaling
FLT3 kinase activity in MOLM13-S cells was more potently
inhibited by PKC412 (near-to-complete inhibition was observed at
25 nM PKC412) than FLT3 kinase activity in drug-resistant cells
(FLT3 kinase activity at 100 nM was comparable to that observed
in untreated cells) (Figure 2A). These results are consistent with the
higher sensitivity observed for MOLM13-S cells to the inhibitory
effects of PKC412 on cell proliferation, as compared to drug-
resistant cells.
As activation of and crosstalk between the RAS/Raf/MEK/
ERK and Jak/STAT signaling pathways play a role in the survival
advantage of leukemic cells driven by mutant FLT3, we were
interested in comparing the expression levels and activity of
relevant signaling components in drug-sensitive and drug-resistant
cells. Higher phospho-MAPK expression was observed in
MOLM13-R-PKC412 cells grown in the continuous presence of
PKC412, as compared to MOLM13-S cells (Figure 2B). Corre-
spondingly, a modest elevation of phospho-MEK expression was
observed in MOLM13-R-PKC412 cells (Figure S2). Paradoxical-
ly, despite over-expression of FLT3 levels in MOLM13-R-
PKC412 and MOLM13-R-HG-7-85-01 cells grown in the
presence of inhibitor, there was a striking decrease in levels of
pSTAT5 in both drug resistant lines, as compared to MOLM13-S
cells (Figure 2C). This finding, however, did not apply to pSTAT3,
which remained unchanged in drug-resistant as compared to
MOLM13-S cells (Figure 2D).
Deregulation of proteins associated with apoptotic signaling is
often associated with drug resistance. As such, we decided to
investigate the expression of proteins including Bcl-2, Mcl-1, Bax,
BIM, BAK, and BID, in MOLM13-R-PKC412 and MOLM13-
R-HG-7-85-01 cells. There was no observation of significant up-
regulation of anti-apoptotic Bcl-2 family proteins or down-
regulation of pro-apoptotic Bcl-2 family proteins (data not shown).
We also investigated the expression of death receptor 5 (DR5), a
member of the tumor necrosis factor receptor (TNFR) family, and
did not observe differences in its expression in drug-sensitive and
drug-resistant cells (data not shown).
FLT3 inhibitor-resistant cells: Drug influence on rate of
proliferation
The rate of growth of drug-resistant cells grown in the
continuous presence of inhibitor was slower than that of
MOLM13-S cells (Figure 3A). This observation was consistent
with a decrease in expression levels of the cell cycle protein, p27
Kip (Figure 3B). Interestingly, however, removal of inhibitor from
the culture medium of drug-resistant cells led to a higher rate of
cell growth similar to that observed in MOLM13-S cells
(Figure 3C).
FLT3 inhibitor-resistant cells: Drug influence on
proliferation and FLT3-associated signaling molecules
Drug withdrawal for several days or weeks resulted in increased
sensitivity of MOLM13-R-PKC412 and MOLM13-R-HG-7-85-01
cells to the inhibitory effects of PKC412 and HG-7-85-01,
respectively, on cell proliferation (Figure S3(A–C)). Consistent with
this, levels of phospho-STAT5 were increased in drug-resistant cells
deprived of inhibitor for several days or several weeks to levels
comparable to those observed in MOLM13-S cells (Figure 4A, B).
Similarly, levels of phospho-MAPK protein in MOLM13-R cells
deprived of inhibitor were comparable to baseline control levels in
MOLM13-S cells (Figure 4C). In addition, withdrawal of HG-7-85-
FLT3 Inhibitor Resistance
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sensitivity of the cells to PKC412, or a partial loss of cross-resistance
to PKC412 (Figure S3(D)), and the withdrawal of PKC412 from
MOLM13-R-PKC412 for 2, 5, and 7 days, or pulsing with 50 nM
PKC412every 2–3daysfor up to 9 days led to a partial loss of cross-
resistance to HG-7-85-01 (Table 1 and Figure S3 (E–I)).
FLT3 inhibitor-resistant cells: Drug influence on FLT3
protein activity, stabilization and half-life
Expression levels of phospho-FLT3 and total FLT3 in drug-
resistant cells deprived of drug for several weeks were comparable
to those observed in MOLM13-S cells (Figure 5A). Drug-resistant
cells deprived of inhibitor for several weeks, however, continued to
show a modest elevation in total cellular tyrosine phosphorylation
as compared to MOLM13-S cells, despite a reduction in FLT3
protein levels to those observed in wt control cells (Figure 5B).
These results, coupled with the fact that prolonged drug
withdrawal from resistant cells did not result in complete reversion
to the drug sensitivity characteristic of wild-type cells, suggest that
the absence of inhibitor in the culture media significantly- but not
completely- abrogates the drug resistant phenotype.
We were interested in investigating the mechanism underlying
the elevated FLT3 expression in drug-resistant cells cultured in the
continuous presence of inhibitor. Drug-sensitive cells treated for
varying periods of time with the protein synthesis inhibitor,
cycloheximide, showed a time-dependent reduction in FLT3
expression, whereas elevated FLT3 expression in drug-resistant
cells appeared to be unaffected by comparable cycloheximide
Figure 1. FLT3 inhibitor-sensitive and FLT3 inhibitor-resistant cells: Comparison of proliferation in the presence of inhibitor,
cellular tyrosine phosphorylation, and FLT3 autophosphorylation. (A) Proliferation/drug sensitivity of drug-sensitive MOLM13-luc+ cells
(MOLM13-S) as compared to MOLM13-luc+ cells exposed for 3 days to gradually increasing concentrations of PKC412 over a span of approximately
three months (MOLM13-R-PCK412). Proliferation study was performed on day 97 since the start of culture of cells in the presence of PKC412. (B)
Proliferation/drug sensitivity of MOLM13-S cells as compared to MOLM13-luc+ cells exposed for 3 days to gradually increasing concentrations of HG-
7-85-01 over a span of approximately three months (MOLM13-R-HG-7-85-01). Proliferation study was performed on day 97 since the start of culture of
cells in the presence of HG-7-85-01. (C) Approximately 2-day HG-7-85-01 treatments of MOLM13-S cells and MOLM13-R-PKC412 cells (made resistant
to 50 nM PKC412 following long-term culture). (D) Approximately 3-day PKC412 treatments of MOLM13-S cells, MOLM13-R-HG-7-85-01 cells (made
resistant to 5 nM HG-7-85-01 following long-term culture), and MOLM13-R-PKC412 cells (made resistant to 50 nM PKC412 following long-term
culture). (E) Phospho-FLT3 and total FLT3 protein expression in drug-sensitive and drug-resistant cells. Protein lysates were prepared from MOLM13-
R-PKC412 cells (resistant to 50 nM PKC412), MOLM13-R-HG-7-85-01 cells (resistant to 10 nM HG-7-85-01), and MOLM13-S cells, and were analyzed via
immunoprecipitation with FLT3 and immunoblotting with antibodies to FLT3 and pTYR. (F) Total cellular tyrosine phosphorylation and total FLT3
protein expression in drug-sensitive and drug-resistant cells. Protein lysates were prepared from MOLM13-R-PKC412 cells(resistant to 50 nM PKC412),
MOLM13-R-HG-7-85-01 cells (resistant to 5 nM HG-7-85-01), and MOLM13-S cells, and were analyzed via immunoblotting with antibodies to FLT3,
pTYR, and alpha-tubulin as a loading control.
doi:10.1371/journal.pone.0025351.g001
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in drug-resistant cells as measured by a longer protein half-life.
Surface expression of FLT3 receptor in FLT3 inhibitor-
sensitive and FLT3 inhibitor-resistant cells
Flow cytometric analysis of FLT3 expression revealed substan-
tially higher FLT3 expression in the drug resistant cells cultured in
the continuous presence of inhibitor as compared to MOLM13-S
cells (Figure 6). Thus, the elevation in FLT3 receptor expression in
resistant cells appears to be predominantly due to increased
surface expression of FLT3. Drug resistant cells cultured in the
absence of inhibitor for several weeks showed FLT3 expression
levels similar to those observed in MOLM13-S cells (Figure S4).
This was again in contrast to the considerably higher surface
expression of FLT3 protein observed in resistant cells cultured in
the continuous presence of inhibitor (Figure S4).
FLT3 mRNA and gene expression in FLT3
inhibitor-sensitive and FLT3 inhibitor-resistant cells
We were interested in investigating whether changes at the
genetic or transcriptional level for FLT3 might contribute to the
aberrant expression of FLT3 protein observed in drug resistant
cells. RT-PCR revealed only a modest up-regulation of FLT3
mRNA in drug-resistant cells cultured in the continuous presence
of inhibitor, with a modest down-regulation of FLT3 in drug-
resistant cells cultured in the prolonged absence of inhibitor
(Figure 7A). Densitometry results suggest on average less than 2-
fold changes in FLT3 mRNA levels (normalized to HPRT) and
changes in FLT3 protein levels ranging from approximately 2.5-5-
fold in drug-sensitive versus drug-resistant cells (normalized to
tubulin or beta-actin). These results suggest that while transcrip-
tional changes might be playing a minor role in FLT3 regulation,
the changes observed at the level of FLT3 protein are more
substantial and likely to be playing a more significant role.
FISH analysis revealed no significant changes in FLT3 gene
copy number in drug-sensitive and drug-resistant cells (Figure 7B–
D). These results argue against FLT3 gene amplification as playing
a significant role in elevation of FLT3 protein expression in drug-
resistant cells.
As an important mechanism of resistance to FLT3 inhibitors is
acquired point mutations in the molecular targets [24,25], and
resistance to PKC412 in patients has been attributed to pre-existing
oracquired mutationsinthe FLT3 kinasedomain[26],wesearched
for FLT3 point mutations by sequencing the FLT3 gene in drug-
sensitive and drug-resistant cells, cultured both in the continuous
presence of inhibitor as well as its absence. No mutations were
detected in the internal tandem duplication domain or kinase
domain of FLT3 in PKC412- or HG-7-85-01-resistant cells.
Cross-resistance in drug-resistant cells to standard
chemotherapy
As evidence exists in support of mutant FLT3 contributing to
resistance of AML to chemotherapeutic agents, we were interested
Figure 2. FLT3 inhibitor-sensitive and FLT3 inhibitor-resistant cells: Comparison of FLT3 kinase activity and tyrosine
phosphorylation of signaling molecules associated with FLT3 signaling. (A) Effects of PKC412 inhibition of phospho-FLT3 in MOLM13-S
and MOLM13-R-PKC412 cells. (B) Phospho-MAPK (p44/42) expression in MOLM13-S and drug-resistant cells as measured by immunoblot. (C–D)
Phospho-STAT expression in MOLM13-S and drug-resistant cells as measured by immunoblot. For A–D, PKC412-resistant MOLM13 cells resistant to
50 nM PKC412 were used, and HG-7-85-01-resistant MOLM13 cells resistant to 10 nM HG-7-85-01 were used.
doi:10.1371/journal.pone.0025351.g002
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FLT3-over-expressing MOLM13-R cells to standard chemother-
apy. Intriguingly, MOLM13-R-PKC412 showed substantially less
sensitivity to the standard chemotherapeutic agent, Ara-c (IC50
was approximately 24.3-fold higher than that of MOLM13-S cells)
(Figure S5). MOLM13-R-HG-7-85-01 and MOLM13-R-PKC412
(CFU) cells, similar to MOLM13-R-PKC412 cells, also showed
less sensitivity to Ara-c (data not shown).
Withdrawal of PKC412 from the culture media for MOLM13-
R-PKC412 cells for three days led to a partial reversal of cross-
resistance to Ara-c (IC50 was approximately 4.3-fold higher than
that of MOLM13-S cells) (Figure S5). Cross-resistance to Ara-c, in
contrast, was not reversed by removal of PKC412 from culture
media for 24 hours, and removal of PKC412 for 8 days led to
partial reversal of Ara-c cross resistance that was more modest
than that observed for the three-day drug withdrawal (Figure S5).
Discussion
While the complexity of the pathogenesis and heterogeneity of
AML is appreciated, the presence in a subset of patients of
mutated FLT3, the ITD variant of which has been shown in
mouse bone marrow transplantation assays to cause a rapidly
lethal myeloproliferative disease in the absence of any significant
block in granulocyte lineage cell differentiation [27], would suggest
the availability of a key therapeutic target that contributes strongly
to the AML phenotype in these patients. As mutant FLT3 likely
enhances proliferation of primitive myeloid cells, one would
predict that FLT3 kinase inhibition would translate into significant
clinical benefit via inhibition of expansion of this cell population.
However, in most clinical trials so far, while responses may be very
rapid, they are typically partial and of very short duration. Thus,
FLT3 inhibitors, as single agents and in combination with
standard therapy, have had limited impact. Since clinical
resistance occurs rapidly, there exists a pressing need to identify
the underlying reason or reasons for the suboptimal clinical
efficacy of FLT3 inhibition.
Causes of FLT3 inhibitor resistance, identified recently in a
relatively small number of studies, have been multi-factorial and
have ranged from identification of Ras mutations, to aberrant
STAT signaling [16], and- through microarray analysis and RT-
PCR- significant over-expression of a notch receptor ligand [17].
Different methodologies used to investigate mechanisms of FLT3
inhibitor resistance could at least partly be attributed to for the
variability in reported resistance mechanisms associated with
FLT3 inhibition, as technologies based on molecular biology and
technologies based on biochemistry can significantly vary in terms
of sensitivity. Even differences in the FLT3 mutations of the cell
lines used for resistance studies might create disparity, as MV4-11
cells have FLT3-ITD in both alleles, and MOLM13 and
MOLM14 cells have one wt FLT3 allele and one FLT3-ITD
allele. However another possibility may be due to the fact that
Figure 3. FLT3 inhibitor-resistant cells: Drug influence on rate of proliferation. (A) Comparison of rate of proliferation of MOLM13-S,
MOLM13-R-PKC412 (cultured in the continuous presence of 50 nM PKC412), and MOLM13-R-HG-7-85-01 (cultured in the continuous presence of
10 nM HG-7-85-01). (B) p27 Kip1 expression in MOLM13-S, MOLM13-R-PKC412 (cultured in the continuous presence of 50 nM PKC412), and MOLM13-
R-HG-7-85-01 (cultured in the continuous presence of 10 nM HG-7-85-01). (C) Cell proliferation of MOLM13-S and drug-resistant cells at various time
points; drug-resistant cells were tested in both the absence and presence of inhibitor. Experiments were performed in triplicate.
doi:10.1371/journal.pone.0025351.g003
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targeted inhibitors,and unlike moreselectiveagents- suchastheAbl
inhibitors used for therapy of CML, may be associated with more
unique and unrelated modes of resistance. For instance, a screening
assay employed to study resistance profiles of three FLT3 inhibitors,
PKC412, SU5614, and sorafenib, showed non-overlapping mech-
anisms of resistance for the three inhibitors [28]. This is in contrast
to the overlapping resistance profiles displayed for ABL inhibitors,
such as imatinib, nilotinib, and dasatinib, which all show resistance
to the T315I gatekeeper mutation [29,30].
There were some similarities observed between the resistance
phenotype described in our studies and those reported by others.
For instance, Piloto et al. reported activation of the Ras/MEK/
MAPK signaling pathway in association with CEP-5214 and CEP-
701 resistance, and we similarly observed elevated phospho-
ERK1/ERK2 and phospho-MEK in MOLM13-R-PKC412 cells,
consistent with elevated FLT3 protein levels. Zhou et al., in
contrast, reported no over-expression of phospho-ERK1/ERK2
in ABT-869-resistant cells, which is a finding consistent with our
observed lack of up-regulation of phospho-ERK1/ERK2 in
MOLM13-R-HG-7-85-01 cells. Zhou et al. reported cross-
resistance of FLT3 inhibitor-resistant lines to structurally unrelated
inhibitors, an observation we made with MOLM13-R-PKC412
and MOLM13-R-HG-7-85-01 cells, as well. Finally, no mutations
in the FLT3 kinase domain or ITD were found in MOLM13-R-
PKC412 and MOLM13-R-HG-7-85-01 cells, consistent with
reports by Zhou et al. and Piloto et al. of no mutations being
detected in the kinase domain of drug-resistant cells. Similarly,
Stolzel et al. reported no mutations in the entire coding region of
FLT3 in resistant cells.
Table 1. Fold differences in IC50 values obtained for HG-7-
85-01-treated MOLM13-R-PKC412 cells cultured in the
presence and absence of PKC412 prior to assay.
Cell type/condition IC50 (fold increase)
MOLM13-S 1
MOLM13-R-PKC412
(continuous PKC412 treatment prior to assay) 2.7
MOLM13-R-PKC412
(condition #1) 1.5
MOLM13-R-PKC412
(condition #2) 1.8
MOLM13-R-PKC412
(condition #3) 0.97
MOLM13-R-PKC412
(condition #4) 1.4
MOLM13-R-PKC412 cells were either in the continuous presence of PKC412
prior to treatment with HG-7-85-01 (PKC412 was washed out on the day of the
set up of the proliferation study), or they were cultured according to the
following treatment conditions: Condition #1: Two-day withdrawal of PKC412
from MOLM13-R-PKC412 cells prior to assay. Condition #2: Two days of PKC412
treatment of MOLM13-R-PKC412, two days of PKC412 withdrawal, three days of
PKC412 treatment, and two days of PKC412 withdrawal prior to assay.
Condition #3: Five days of PKC412 withdrawal prior to assay. Condition #4:
Seven days of PKC412 withdrawal prior to assay. IC50 values are presented as
fold increases over IC50 obtained for HG-7-85-01 against MOLM13-S cells.
doi:10.1371/journal.pone.0025351.t001
Figure 4. FLT3 inhibitor-resistant cells: Drug influence on FLT3-associated signaling molecules. (A) Phospho-STAT5 and FLT3 expression
in drug-resistant cells cultured in the continuous presence of drug, or the absence of drug for 4 days. For this study, PKC412-resistant MOLM13 cells
resistant to 50 nM PKC412 were used, and HG-7-85-01-resistant MOLM13 cells resistant to 10 nM HG-7-85-01 were used. (B) Phospho-STAT5
expression and (C) phospho-MAPK expression in PKC412-resistant cells cultured in the continuous presence of 50 nM PKC412 or its absence for 3
weeks.
doi:10.1371/journal.pone.0025351.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25351Our findings suggest significant over-expression of membrane
surface-bound FLT3 receptor in FLT3 inhibitor-resistant cells,
which appears to be due to drug-dependent stabilization and
FLT3 half-life prolongation. This is in contrast to findings reported
in Zhou et al., in which immunoblotting showed similar levels of
FLT3 and phospho-FLT3 in drug-sensitive and –resistant cells.
However, in our studies, RT-PCR showed only modest changes in
FLT3 receptor levels between drug-sensitive and –resistant cells,
and FISH analysis revealed no evidence for FLT3 gene
amplification. These findings are consistent with those of Stolzel
et al., in which microarray data and quantitative PCR did not
reveal differential FLT3 expression between wt and drug-resistant
cells.
Levels of phospho-STAT5, however not total STAT5, in our
study were found to be dramatically suppressed in MOLM13-R-
PKC412 and MOLM13-R-HG-7-85-01 cells cultured in the
continuous presence of inhibitor, whereas levels of phospho-
STAT3 and total STAT3 were unchanged. We hypothesize that
the reduction in phospho-STAT5 in resistant cells might be a
drug-dependent compensatory homeostatic mechanism, as resis-
tant cells over-expressing FLT3 and characterized by elevated
phospho-ERK1/ERK2 and phospho-MEK may not be able to
tolerate overactive FLT3 signaling. Indeed, when FLT3 inhibitor
is removed from the culture media, levels of phospho-STAT5
return to normal and levels of FLT3 protein decrease to the
baseline levels observed in drug-sensitive control cells. Zhou et al.,
in contrast, reported over-expression of phospho-STAT5 in ABT-
869-resistant cells (as measured by immunoblotting), as well as
other members of the STAT family. In the case of ABT-869-
resistant cells, it is possible that there would be no similar need for
a compensatory homeostatic mechanism characterized by down-
regulation of phospho-STAT5, as ABT-869-resistant cells, unlike
the drug-resistant cell lines described here, show normal FLT3
protein and phospho-ERK1/ERK2 expression levels. The
presence or absence of inhibitor in the culture media is also a
variable that needs to be taken into consideration when
measurement of the expression or activity of drug-responsive
signaling pathway components, as resistant cells in the Zhou et al.
study were grown in normal medium without ABT-869 for at least
48 hours before experiments.
The over-expression of FLT3 observed in two cell lines made
resistant to two structurally-unrelated FLT3 inhibitors raises the
notion that FLT3 inhibitor exposure may impede the efficacy of
these inhibitors by increasing levels of the target FLT3 protein-
hence a possible mechanism contributing to their lack of efficacy in
the clinic. Our data correlate with other findings, for instance the
transient inhibition in Phase I trials of FLT3 in KW-2449-treated
patients to less than 20% of baseline [31]. It has also been shown
that, in at least some primary AML cells, there is continued
phosphorylation of ERK, STAT5, or AKT following inhibition of
Figure 5. FLT3 inhibitor-resistant cells: Drug influence on FLT3 protein activity, stabilization and half-life. (A) Phospho-FLT3 and total
FLT3 protein expression in MOLM13-S cells, as compared to MOLM13-R-PKC412 cells (cultured in the continuous presence of 50 nM PKC412 or its
absence for 3 weeks). Protein lysates were prepared and analyzed via immunoprecipitation with FLT3 and immunoblotting with antibodies to FLT3
and pTYR. (B) Total cellular tyrosine phosphorylation and total FLT3 protein expression in MOLM13-S cells, as compared to MOLM13-R-PKC412 cells
(cultured in the continuous presence of 50 nM PKC412 or its absence for 3 weeks). Protein lysates were prepared and analyzed via immunoblotting
with antibodies to FLT3, pTYR, and beta-actin as a loading control. (C) Cycloheximide (10 mg/mL) treatment of MOLM13-S cells and MOLM13-R-
PKC412 cells for the indicated times.
doi:10.1371/journal.pone.0025351.g005
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inhibitors used as single agents for the treatment of mutant FLT3-
positive AML [32]. In addition, it has recently been shown that
FLT3-ITD inhibition of autophosphorylation does not always
result in cell death, which raises the question of the importance of
FLT3 signaling for some mutant FLT3-positive AML [33].
Indeed, there are alternative signaling pathways that have been
shown to be important in causing drug resistance, such as
aberrant, constitutively active PI3K/Akt-mediated signaling in
AML, and over-expression of Cdc28 protein kinase regulatory
subunit 1B (CKS1B), which leads to activation of Jak/STAT3 and
MEK/ERK signaling pathways in multiple myeloma [34,35]. It is
therefore anticipated that the limited clinical efficacy of FLT3
inhibitors may be due to their inability to elicit sustained, complete
responses in patients [36].
We have previously implicated FLT3-ITD protein over-expres-
sion in secondary FLT3 inhibitor resistance [11]. In clinical trials,
FLT3 inhibitor treatment and myelosuppressive chemotherapy
have been implicated in inducing FLT3 ligand expression and/or
FLT3 cell surface expression [14,37]. In the Knapper et al. study,
clinical effects were only transient decreases in peripheral blood and
marrowblasts in60% of mutant FLT3-expressing patients and 23%
of wild-type FLT3 patients. The majority (13) of 14 patients that
FLT3 protein levels were able to be measured on day 0 of treatment
and on at least one time point during treatment with lestaurtinib
demonstrated increases in blast surface FLT3 expression during in
vivo FLT3 inhibitor treatment. Authors of this study proposed the
notion that this elevation in blast surface FLT3 expression could
potentially play a role in drug resistance/limited FLT3 inhibitor
efficacy. Alternatively, they suggested that lestaurtinib exposure
simply leads to a return of inactivated cellular FLT3 to the cell
membrane. In this same investigation, at least two patients (one
wild-type and one mutant FLT3-expressing) showed prolonged
clinicalresponsestolestaurtinibthat peakedseveralweeksafterdrug
withdrawal. Other studies have correlated over-expression of FLT3
protein with disease relapse [38], and over-expression of FLT3
transcript levels with risk of relapse, and a high percentage of bone
marrow blasts and leukocyte counts [39,40].
In non-small cell lung cancer (NSCLC), both the over-
expression of epidermal growth factor receptor (EGFR) and
MET have been implicated in transformation, and it has been
suggested that the inhibition of EGFR can be bypassed by
activated MET [41]. Similarly, it may be possible that FLT3
inhibition in AML is not sufficient as other tyrosine kinase
inhibitors might take over the function of this oncoprotein.
Our findings suggest that there may be benefit to the use of
sequential combination therapy as a way to enhance the efficacy of
FLT3 inhibitors and override development of drug resistance. As
we did not observe between MOLM13-S and MOLM13-R cells
any significant differences in intrinsic or extrinsic apoptotic
pathway-related proteins such as members of the Bcl-2 family or
levels of DR5, it is conceivable that combined treatment using a
FLT3 inhibitor and inhibitor of apoptotic signaling may be
successful in overriding drug resistance. Indeed, we observed a
positive combination effect between the IAP inhibitor, LCL161,
and PKC412, against MOLM13-R-PKC412 cells, even when
cultured in the presence of protective secreted cytokines in stromal
conditioned media (Figure S6). Our data also point toward the
potential use of FLT3 antibodies or other FLT3 target-specific
therapies as a way to override drug resistance.
In addition, the fact that FLT3 inhibitor treatment might
contribute to an increase in target protein that- over time- lowers
drug sensitivity of mutant FLT3-expressing cells (while patients are
still being treated, even if this might be reversible upon withdrawal
of the drug) could be proposed as one possible reason why FLT3
inhibitors might not be as clinically effective as one might predict-
seeing that development of clinical inhibitors of mutant FLT3 is
biorationally-speaking a promising approach. Indeed, we observed
an increase in PKC412 sensitivity of MOLM13-R-PKC412
deprived of PKC412 for varying lengths of time, as well as an
increase in HG-7-85-01 sensitivity of MOLM13-R-HG-7-85-01
cells deprived of HG-7-85-01. We also observed a decrease in the
extent of cross-resistance of MOLM13-R-PKC412 cells to HG-7-
85-01 and MOLM13-R-HG-7-85-01 cells to PKC412 following
removal of the FLT3 inhibitor each line was made resistant to,
respectively. Thus, withdrawing the drug cells are resistant to may
be a first step in regaining drug sensitivity, and introducing in
tandem another drug (i.e. another FLT3 inhibitor) would
potentially be a second step in killing the resistant cells as cross-
resistance is reversed by removal of the first drug.
We found the observed decrease in sensitivity of both
MOLM13-R-PKC412 and MOLM13-R-HG-7-85-01 cells to
Figure 6. Surface expression of FLT3 receptor in FLT3 inhibitor-
sensitive and FLT3 inhibitor-resistant cells. Flow cytometry was
performed using a CD-135-PE antibody for detection of FLT3 receptor
surface expression in MOLM13-S cells (A) versus MOLM13-R-PKC412
cells (cultured in the continuous presence of 50 nM PKC412). (B) An IgG
aPE (1) antibody was used as a control (shown in C). For A: No staining
MOLM13-S control (PE-A median: 126); MOLM13-S stained with CD135-
PE antibody (PE-A median: 497). For B: No staining MOLM13-R-PKC412
control (in presence of PKC412) (PE-A median: 134); MOLM13-R-PKC412
(in presence of PKC412) stained with CD135-PE antibody (PE-A median:
951). For C: No staining MOLM13-S control (PE-A median: 129);
MOLM13-S stained with IgG aPE (1) control antibody (PE-A median:
156). Shaded=background.
doi:10.1371/journal.pone.0025351.g006
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the limited clinical efficacy observed with combination treatment
involving FLT3 inhibitors and standard chemotherapy. As there is
evidence in support of mutant FLT3 itself contributing to
resistance of AML to chemotherapeutic agents, we hypothesize
that perhaps the decreased Ara-c sensitivity may be due to the
over-expression of FLT3 common to both resistant cell popula-
tions. For instance, induced FLT3-ITD expression in myeloid cells
was observed to correlate with Ara-c resistance due to decreased
cellular uptake of Ara-c [42]. Drug resistance was accompanied by
down-regulation of a transporter responsible for Ara-c cellular
uptake, equilibrative nucleoside transporter 1 (ENT1), possibly
mediated by upregulation of hypoxia inducible factor 1 alpha
subunit (HIF1A) [42].
Cross-resistance to Ara-c, similar to cross-resistance to HG-7-
85-01, was partially reversed by several day withdrawal of
PKC412 from the culture medium of MOLM13-R-PKC412 cells.
These results, taken together, may inspire clinicians to attempt to
alter the schedule of treatment with certain FLT3 inhibitors,
including sequential administration of more than one FLT3
inhibitor, or sequential administration of a FLT3 inhibitor and
standard chemotherapy, such as Ara-c, as strategies to optimize
efficacy and induce more sustained clinical responses in patients.
However, as sequential administration of chemotherapy (first)
followed by FLT3 inhibitors (last) has proven to be beneficial for
FLT3 inhibitors such as CEP-701 [43], other FLT3 inhibitors,
such as tandutinib, are able to synergize with standard
chemotherapy in a sequence-independent fashion [44]. Consider-
ing the distinct mechanisms of resistance exhibited by FLT3
inhibitors studied thus far, the nature of each individual FLT3
inhibitor should therefore be taken into consideration when
optimizing therapeutic strategies.
Supporting Information
Figure S1 PKC412-resistant cell line (resistant to
100 nM PKC412) developed from Colony Forming Units
(CFUs). (A) Colony assays: MOLM13-luc+ cells seeded. 100
cells/0.1 mL in IMDM. 900 uL Metho Cult. Total/well=1 mL.
Stem Cell Technologies ‘‘Metho Cult’’. Methylcellulose cat #
4230 without cytokines. 9 days between seeding cells and counting.
(B) PKC412-resistant cell line (resistant to 100 nM PKC412)
developed from Colony Forming Units (CFUs) (MOLM13-R-
PKC412 (CFU): pTYR levels and FLT3 protein levels. 12/10/09
FLT3 I.P./western for PKC412-resistant colony (derived from
MOLM13-luc+ cells), and compared to wt MOLM13-luc+ cells in
culture. For I.P./western, FLT3 Ab (1:2000). For development of
Figure 7. FLT3 mRNA and gene expression in FLT3 inhibitor-sensitive and FLT3 inhibitor-resistant cells. (A) RT-PCR was performed for
comparison of FLT3 mRNA levels in MOLM13-S cells and drug-resistant cells cultured in the absence and presence of drug. This study is
representative of two independent studies in which similar results were observed. (B–D) FISH analysis was performed for comparison of FLT3 gene
expression in MOLM13-S cells (B) and drug-resistant cultured in the presence (C) and .3 week absence (D) of drug.
doi:10.1371/journal.pone.0025351.g007
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25351MOLM13-R-PKC412 (CFU) cells, colony assays were initially
performed in which 100 MOLM13-luc+ cells/0.1 mL in IMDM
were seeded +900 uL ‘‘complete’’ methylcellulose medium
containing recombinant cytokines (contents: fetal bovine serum,
rh SCF, rh GM-CSF, rh IL-3, Bovine Serum Albumin,
methylcellulose in Iscove’s MDM, 2-Mercaptoethanol, rh Eryth-
ropoietin, L-Glutamine) (MethoCult GFH4434, StemCell Tech-
nologies, Inc., Vancouver, BC). The plates also contained
PKC412 at the indicated concentrations. The plates were
incubated at 37uC in 5% CO2 for .1 week, and then myeloid
and erythroid colonies (early progenitors with erythroid and
myeloid components: CFU-GM, CFU-E, BFU-E, and CFU-
GEMM) were counted on an inverted microscope. There was a
total of nine days between seeding cells and counting and drug-
resistant colony selection, pooling of colonies, and culture of
colonies.
(TIF)
Figure S2 Phospho-MEK expression in MOLM13-R-
PKC412 and MOLM13-R-HG-7-85-01 cells. Protein expres-
sion was assessed by immunoblotting.
(TIF)
Figure S3 (A–D). Effects of FLT3 inhibitor withdrawal
on proliferation of FLT3 inhibitor-resistant cells. (A–B)
Effects of short-term drug withdrawal on MOLM13-R-PKC412
and MOLM13-R-HG-7-85-01 cells. (C) Effects of over three week
drug withdrawal on MOLM13-R-PKC412 cells. (D) Drug
washout experiment: six-day drug withdrawal: effects on prolifer-
ation of MOLM13-R-HG-7-85-01 in the presence of PKC412.
(E–H). Effects of FLT3 inhibitor withdrawal on prolifer-
ation of FLT3 inhibitor-resistant cells. Condition #1: Two-
day withdrawal of PKC412 from MOLM13-R-PKC412 cells
prior to assay. Condition #2: Two days of PKC412 treatment of
MOLM13-R-PKC412, two days of PKC412 withdrawal, three
days of PKC412 treatment, and two days of PKC412 withdrawal
prior to assay. Condition #3: Five days of PKC412 withdrawal
prior to assay. Condition #4: Seven days of PKC412 withdrawal
prior to assay.
(TIF)
Figure S4 Flow cytometry analyzing surface expression
of FLT3 receptor in drug-sensitive cells versus drug-
resistant cells cultured in the absence and presence of
inhibitor.
(TIF)
Figure S5 Cross resistance of MOLM13-R-PKC412 cells
to standard chemotherapy. (A) Comparison of sensitivity to
Ara-c of MOLM13-S and MOLM13-R-PKC412 cells in the
continuous presence of PKC412 and following 24 hours of
PKC412 withdrawal. (B) Comparison of sensitivity of Ara-c of
MOLM13-S and MOLM13-R-PKC412 cells in the continuous
presence of PKC412 and following 3-days of PKC412 withdrawal.
(C) Comparison of sensitivity of Ara-c of MOLM13-S and
MOLM13-R-PKC412 cells in the continuous presence of
PKC412 and following 8-days of PKC412 withdrawal.
(TIF)
Figure S6 Effects of combination of LCL161 and
PKC412 on PKC412-resistant leukemia cells. (A) Stro-
mal-mediated rescue of PKC412-resistant MOLM13-S cells
cultured for approximately 3 days in the presence of PKC412.
(B) Approximately 3-day treatment of MOLM13-R-PKC412
(cultured in the absence of stromal conditioned media, or SCM)
with PKC412, LCL161, or a combination of PKC412 and
LCL161. (C) Approximately 3-day treatment of MOLM13-R-
PKC412 cells (cultured in the presence of SCM) with PKC412,
LCL161, or a combination of PKC412 and LCL161. This study
was performed with one fixed concentration (1000 nM) of
LCL161.
(TIF)
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